Affiliated Treatment Facilities
1515 Holcombe Boulevard
Main Building, Elevator B Floor 9
Houston, TX 77030
01. Doctor Overview
Doctor Overview
Dr. Carl M. Gay is a board-certified medical oncologist in Houston, Texas. He specializes in lung cancer and other chest conditions, including mesothelioma. He treats patients at the University of Texas MD Anderson Cancer Center, where he is also an assistant professor.
Dr. Gay has a Ph.D. in biology and a medical degree from the New York University School of Medicine. He continued his medical training with a residency in internal medicine at the University of Texas Health Science Center. Afterward, Dr. Gay completed his fellowship training in medical oncology at MD Anderson Cancer Center.
Research plays a significant role in Dr. Gay’s career. He has co-authored more than 15 peer-reviewed articles. He is currently part of four separate clinical trials, with two focusing on lung cancers. He has also studied chemotherapy in recurrent malignant mesothelioma.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Medical Oncology
Other Interests & Specialties: Mesothelioma, lung cancer, brain cancer, endocrine gland cancer, metastatic respiratory system cancer, neuroendocrine tumors, pleural cancer and thyroid cancer.
Certifications, Awards & Accolades: American Board of Internal Medicine certification in Medical Oncology, recipient of the MD Anderson Excellence in Science Award (2021), Lung Cancer Alliance Young Investigator Award
Education & Experience:
- Medical Degree from New York University School of Medicine
- Residency in Internal Medicine at the University of Texas Health Science Center
- Fellowship in Medical Oncology at the University of Texas MD Anderson Cancer Center
03. Publications
Publications
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 Mar 8;39(3):346-360.e7.
A phase ii trial of alisertib (Mln8237) in salvage malignant mesothelioma. Oncologist. 2020 Oct;25(10):e1457–63.
Differential sensitivity analysis for resistant malignancies (Disarm) identifies common candidate therapies across platinum-resistant cancers. Clin Cancer Res. 2019 Jan 1;25(1):346–57.
Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018 Dec;8(12):1548–65.